- Email: [email protected]
Alk Translocation in Sarcomatoid Carcinoma of Head and Neck and Treatment Effect of Crizotinib: a Case Series
Annals of Oncology 25 (Supplement 5): v75–v109, 2014 doi:10.1093/annonc/mdu436.7
Poster Session (Poster presentations categorized by each organ) P1
3
4
abstracts
Sungmin Kim1, Myung-Ju Ahn1, Jong-Mu Sun1, Keunchil Park1, Moon Jin Kim1, Yunla Choi2, Young Hye Go2, Chung-Hwan Baek3, Young-Ik Son3 1 Division of Hematology-Oncology, Department of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine 2 Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine 3 Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v76/2240514 by guest on 24 October 2019
ALK TRANSLOCATION IN SARCOMATOID CARCINOMA OF HEAD AND NECK AND TREATMENT EFFECT OF CRIZOTINIB: A CASE SERIES
Sarcomatoid carcinoma of the upper aerodigestive tract, a variant of squamous cell carcinoma, is a rare biphasic tumor consisting of epithelial and mesenchymal components. Herein, we report a case of 34-year-old woman who had a sarcomatoid carcinoma in maxillary sinus and had been treated with surgery, radiation therapy and multiple lines of palliative chemotherapy. Because ALK translocation is common in sarcoma, ALK FISH was performed on the tumor tissue and showed break-apart signal indicative of ALK translocation. Thus, ALK inhibitor, crizotinib was administered to the patient. Although dramatic response was not observed, clinical improvement and stable disease with minimal tumor shrinkage was noted and lasted for 4 months. To further identify the incidence of ALK rearrangement in sarcomatoid carcinoma of head and neck, ALK FISH was performed on tumor samples of 10 patients. Among them, two patients were positive for ALK FISH. To the best of our knowledge, this is the first case report demonstrating clinical benefit of crizotinib in in sarcomatoid carcinoma of head and neck with confirmed ALK translocation . Our results suggest that ALK FISH test may be suitable and encouraged for patients with sarcomatoid carcinoma of head and neck.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Poster Session (Poster presentations categorized by each organ) P1
3
4
abstracts
Sungmin Kim1, Myung-Ju Ahn1, Jong-Mu Sun1, Keunchil Park1, Moon Jin Kim1, Yunla Choi2, Young Hye Go2, Chung-Hwan Baek3, Young-Ik Son3 1 Division of Hematology-Oncology, Department of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine 2 Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine 3 Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v76/2240514 by guest on 24 October 2019
ALK TRANSLOCATION IN SARCOMATOID CARCINOMA OF HEAD AND NECK AND TREATMENT EFFECT OF CRIZOTINIB: A CASE SERIES
Sarcomatoid carcinoma of the upper aerodigestive tract, a variant of squamous cell carcinoma, is a rare biphasic tumor consisting of epithelial and mesenchymal components. Herein, we report a case of 34-year-old woman who had a sarcomatoid carcinoma in maxillary sinus and had been treated with surgery, radiation therapy and multiple lines of palliative chemotherapy. Because ALK translocation is common in sarcoma, ALK FISH was performed on the tumor tissue and showed break-apart signal indicative of ALK translocation. Thus, ALK inhibitor, crizotinib was administered to the patient. Although dramatic response was not observed, clinical improvement and stable disease with minimal tumor shrinkage was noted and lasted for 4 months. To further identify the incidence of ALK rearrangement in sarcomatoid carcinoma of head and neck, ALK FISH was performed on tumor samples of 10 patients. Among them, two patients were positive for ALK FISH. To the best of our knowledge, this is the first case report demonstrating clinical benefit of crizotinib in in sarcomatoid carcinoma of head and neck with confirmed ALK translocation . Our results suggest that ALK FISH test may be suitable and encouraged for patients with sarcomatoid carcinoma of head and neck.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].